COVID-19 is an infectious disease caused by SARS-CoV2 virus. The objective of our study is to analyze the progression and the severity of COVID-19 in patients with RA. Indeed, few data are available on this subject, and this would allow us to improve management of COVID-19 in these potential at-risk patients.
Study Type
OBSERVATIONAL
Enrollment
2,000
UH Montpellier
Montpellier, France
Hospitalization rates for COVID-19
Proportion of hospitalized patients in RA group or control group. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Time frame: 1 day
Critical care transfer rate for COVID-19 and death due to COVID-19
Proportion of patients transferred in critical care for COVID-19 or deaths due to COVID-19 From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Time frame: 1 day
Pulmonary comorbidities, corticosteroids or DMARDs use
Type and severity of patients pulmonary comorbidities and treatment by corticosteroids or DMARDs in RA group From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Time frame: 1 day
Age
Patients demographics From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Time frame: 1 day
Number of Participants with co-morbidities
Patients comorbidities From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Time frame: 1 day
Type of clinical presentation
Patients COVID-19 clinical presentation From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Time frame: 1 day
Type of associated treatments
From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 1 day